Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study

被引:4
|
作者
Ojha, Rohit P. [1 ]
Hanzis, Christina A. [2 ]
Hunter, Zachary R. [2 ]
Greenland, Sander [3 ,4 ]
Offutt-Powell, Tabatha N. [5 ]
Manning, Robert J. [2 ]
Lewicki, Megan [2 ]
Brodsky, Philip S. [2 ]
Ioakimidis, Leukothea [2 ]
Tripsas, Christina K. [2 ]
Patterson, Christopher J. [2 ]
Sheehy, Patricia [2 ]
Singh, Karan P. [6 ]
Treon, Steven P. [2 ,7 ]
机构
[1] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA
[4] Univ Calif Los Angeles, Coll Letters & Sci, Dept Stat, Los Angeles, CA USA
[5] Univ N Texas, Hlth Sci Ctr, Dept Epidemiol, Sch Publ Hlth, Ft Worth, TX USA
[6] Univ N Texas, Hlth Sci Ctr, Dept Biostat, Sch Publ Hlth, Ft Worth, TX USA
[7] Harvard Univ, Sch Med, Boston, MA USA
关键词
Waldenstrom Macroglobulinemia; Epidemiology; Family history; Risk factor; Breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Prostate cancer; MUTATIONS;
D O I
10.1016/j.canep.2011.10.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Little is known about the epidemiology and etiology of Waldenstrom macroglobulinemia (WM). Despite several studies of the relation between family history and B-cell disorders and WM, family history of non-hematologic cancers has not been systematically investigated. We thus examined associations of family history of breast, colorectal, lung, ovarian, and prostate cancers with WM. Methods: All probands aged 20-79 years with bone marrow biopsy-confirmed diagnosis of WM between May 1, 1999 and January 1, 2010 at the Bing Center for Waldenstrom Macroglobulinemia were eligible for inclusion in our analysis. We reviewed medical records for eligible probands to determine family history of cancer (defined as a cancer diagnosis for >1 first-degree relative(s) of the proband). Using expected values constructed from the United States National Health Interview Survey, we estimated age- and race-standardized rate ratios (RRs) for family history of breast, colorectal, lung, ovarian, and prostate cancers by WM subtype. Results: Family history of prostate cancer had the largest overall rate ratio (RR = 1.4, 95% confidence limits [CL]: 1.1, 1.7), and among sporadic cases, family history of prostate and breast cancer had the largest rate ratios (prostate: RR = 1.3, 95% CL: 1.1, 1.7; breast: RR = 1.3, 95% CL: 1.2, 1.6). Conclusion: Our study suggests that it may be worthwhile to pursue these associations in a case-control study with uniform selection and data collection for cases and controls, and at least some record-based information on family history. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:294 / 297
页数:4
相关论文
共 50 条
  • [1] Clinical and Immunologic Characteristics of Non-Hematologic Cancers in Patients with Inborn Errors of Immunity
    Delavari, Samaneh
    Wang, Yating
    Shad, Tannaz Moeini
    Pashangzadeh, Salar
    Nazari, Farzad
    Salami, Fereshte
    Abolhassani, Hassan
    CANCERS, 2023, 15 (03)
  • [2] CAUSES OF DEATH IN PATIENTS WITH NON-HEMATOLOGIC MALIGNANCIES
    RODRIGUEZ, V
    INAGAKI, J
    BODEY, GP
    CANCER CHEMOTHERAPY REPORTS PART 1, 1973, 57 (01): : 103 - 103
  • [3] Incidence of second non-hematologic malignancies in patients with multiple myeloma
    Fernandez-Ruiz, M.
    Guerra-Vales, J. M.
    Llenas-Garcia, J.
    Colina-Ruiz Delgado, F.
    REVISTA CLINICA ESPANOLA, 2010, 210 (01): : 50 - 51
  • [4] Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
    Coombs, Catherine C.
    Zehir, Ahmet
    Devlin, Sean M.
    Kishtagari, Ashwin
    Syed, Aijazuddin
    Jonsson, Philip
    Hyman, David M.
    Solit, David B.
    Robson, Mark E.
    Baselga, Jose
    Arcila, Maria E.
    Ladanyi, Marc
    Tallman, Martin S.
    Levine, Ross L.
    Berger, Michael F.
    CELL STEM CELL, 2017, 21 (03) : 374 - +
  • [5] Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia
    Hanzis, Christina
    Hunter, Zachary
    Manning, Robert
    Lewicki, Megan
    Brodsky, Philip
    Ioakimidis, Leukothea
    Tripsas, Christina
    Patterson, Christopher
    Sheehy, Patricia
    BLOOD, 2010, 116 (21) : 1692 - 1693
  • [6] Survival outcomes of secondary cancers in patients with waldenstrom macroglobulinemia: An analysis of the SEER database
    Castillo, Jorge J.
    Olszewski, Adam J.
    Kanan, Sandra
    Meid, Kirsten
    Hunter, Zachary R.
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (08) : 696 - 701
  • [7] "High Treg" Inflammations Promote (Most) Non-Hematologic Cancers While "Low Treg" Inflammations Promote Lymphoid Cancers
    Elkoshi, Zeev
    JOURNAL OF INFLAMMATION RESEARCH, 2020, 13 : 209 - 221
  • [8] Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
    Kuter, David J.
    HAEMATOLOGICA, 2022, 107 (06) : 1243 - 1263
  • [9] Lower Risk of Platelet Antibody Production in Hematologic Patients after Platelet Transfusions Than Non-Hematologic Patients
    Lin, Jeong-Shi
    Lee, Li-Hsuan
    Liu, Hsueng-Mei
    Chen, Ying-Ju
    Chiou, Tzeon-Jye
    TRANSFUSION, 2018, 58 : 181A - 182A
  • [10] The impact of prior history of non-hematologic malignancies on time to first treatment and overall survival among individuals with CLL or MBL
    Vallejo, Bryan A.
    Allmer, Cristine
    Rabe, Kari G.
    Robinson, Dennis P.
    Wang, Yucai
    Hampel, Paul J.
    Braggio, Esteban D.
    Kay, Neil E.
    Cerhan, James R.
    Parikh, Sameer A.
    Slager, Susan L.
    CANCER RESEARCH, 2024, 84 (06)